Thoratec gets final FDA approval to expand enrollment of HeartMate III U.S. clinical trial

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites.



from The Medical News http://ift.tt/1CWasgr